Signals
13Adolescent depression care widens past SSRI defaults
Esketamine adolescent indication consideration, ECT and TMS adolescent access, structured measurement-based care, and integrated school-and-medical models are reshaping adolescent depression care.
Treatment-resistant schizophrenia care formalises around clozapine integration
Clozapine pathway formalisation, KarXT muscarinic mechanism integration, and emerging mechanism-targeted programs are reshaping treatment-resistant schizophrenia.
Autism spectrum disorder pharmacotherapy options widen past irritability indications
Risperidone and aripiprazole maturity for ASD-associated irritability, emerging mechanism-targeted programs for core symptoms, and integrated multidisciplinary care models are reshaping ASD pharmacotherapy.
Cannabis use disorder pharmacotherapy programs reach late-stage trials
Late-stage cannabis use disorder pharmacotherapy programs and integrated behavioural-and-pharmacological care models are emerging in a previously bare category.
Tobacco use disorder pharmacotherapy widens past nicotine replacement and varenicline
Cytisine availability, novel nicotine receptor pharmacotherapy, and integrated behavioural-and-pharmacological care delivery are reshaping tobacco use disorder management.
Insomnia comorbid with mental health conditions acquires structured therapy options
Daridorexant maturity, cognitive-behavioural therapy for insomnia (CBT-I) digital expansion, and integrated mental-health-and-insomnia treatment models are reshaping comorbid insomnia care.
Dementia behavioural symptoms acquire approved pharmacotherapy
Brexpiprazole approval for agitation in Alzheimer's dementia and follow-on programs are reshaping dementia behavioural symptom management.
Obsessive-compulsive disorder modern options mature
Deep brain stimulation maturity, novel glutamate-modulator programs, and refined transcranial magnetic stimulation protocols are reshaping refractory OCD management.
OCD and intractable-condition options widen
Deep brain stimulation, transcranial magnetic stimulation, and emerging psychedelic-assisted therapy are all reaching into refractory OCD.
Adult ADHD prescribing patterns are being reshaped by stimulant supply normalisation
The acute stimulant supply shortages that characterised 2022 to 2024 in adult ADHD are normalising. Prescribing patterns are stabilising at higher absolute levels than pre-shortage, with implications for both the established stimulant class and the non-stimulant pipeline.
Long-acting injectable antipsychotic uptake reveals adherence-versus-access gap in schizophrenia
Real-world uptake of long-acting injectable (LAI) antipsychotics in schizophrenia is well below the eligible-population estimate across major markets, despite strong adherence and outcome benefits. The drivers are access infrastructure, prescriber inertia, and patient-pathway operational complexity.
Schizophrenia pipeline shifts from D2 to muscarinic mechanisms
The schizophrenia therapeutic pipeline is shifting from the dopamine D2 receptor mechanism that has defined antipsychotic therapy for fifty years toward muscarinic receptor mechanisms with substantively different efficacy and tolerability profiles. The implications for the schizophrenia commercial category are material.
Psychedelic-assisted therapy: clinical pipeline progress, regulatory caution
MDMA- and psilocybin-based therapies have advanced through late-stage trials, but the FDA's measured response - and the system requirements those therapies impose on delivery - mean rollout will be slower and more constrained than mechanism enthusiasm suggested.
Snapshots
6Treatment-resistant schizophrenia therapy reference (2026)
Reference snapshot of TRS therapy across clozapine, augmentation, and emerging mechanism tiers.
Autism spectrum disorder care reference (2026)
Reference snapshot of ASD care across behavioural therapy, educational support, pharmacotherapy for associated symptoms, and emerging core-symptom programs.
Tobacco use disorder therapy reference (2026)
Reference snapshot of tobacco use disorder therapy across pharmacotherapy, behavioural support, and integrated care models.
OCD therapy reference (2026)
Reference snapshot of OCD therapy across pharmacotherapy, psychotherapy, and procedural-and-emerging tiers.
Bipolar disorder treatment landscape, 2026 mid-year reference
Reference layout of the bipolar disorder treatment landscape as of mid-2026: mood stabilisers, atypical antipsychotics, antidepressant adjuncts, the depression-versus-mania-versus-maintenance prescribing logic, and the live commercial questions across the pipeline.
Treatment-resistant depression pipeline, 2026 mid-year reference
Reference layout of the treatment-resistant depression pipeline as of mid-2026: approved mechanisms, late-stage assets, the psychedelic and ketamine-class programs, novel non-monoamine mechanisms, and the live commercial questions across the pipeline.
Explained
5What is treatment-resistant schizophrenia?
Plain-language primer on treatment-resistant schizophrenia, why clozapine matters, and what comprehensive care looks like.
Autism spectrum disorder care explained
Plain-language primer on ASD care, why it is multidisciplinary, and what is changing in pharmacotherapy.
What is tobacco use disorder?
Plain-language primer on tobacco use disorder, why quitting is difficult, and what the modern combined approach can offer.
What is obsessive-compulsive disorder?
Plain-language primer on OCD, why it has multiple subtypes, and what therapy can offer.
How pediatric mental health prescribing differs from adult and why it matters
Pediatric mental health prescribing operates under different evidence frameworks, regulatory expectations, and access structures than adult prescribing. Understanding the differences is essential for any sponsor with mental health assets that are eligible for paediatric expansion or that interact with paediatric-eligible populations.